Evidence map›Paper›PMID 40790123›Full record

ArticleNPJ vaccines2025

Immunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines.

C Buddy Creech, Mariana Leguia, Johannes B Goll, Leigh M Howard, Antón Vila-Sanjurjo, Sandra Yoder, Diana Juarez, Alejandra Garcia-Glaessner, Casey E Gelber, Natalia Jimenez-Truque and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. CD4+ T-cell immunity toDiscover immunity · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

C Buddy CreechVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA. buddy.creech@vumc.org.
Mariana LeguiaGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
Johannes B GollDepartment of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, USA.
Leigh M HowardVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Antón Vila-SanjurjoCICA - Centro Interdisciplinar de Química e Bioloxía, Departamento de Bioloxía, Facultade de Ciencias, Universidade da Coruña, A Coruña, Spain.
Sandra YoderVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Diana JuarezGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
Alejandra Garcia-GlaessnerGenomics Laboratory, Pontificia Universidad Católica del Perú (PUCP), Lima, Peru.
Casey E GelberDepartment of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, USA.
Natalia Jimenez-TruqueDepartment of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, USA.
Sami CherikhDepartment of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, USA.
Ana I GilInstituto de Investigación Nutricional, Lima, Peru.
James E CroweVanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, TN, USA.
Rubelio Cornejo CotosInstituto de Investigación Nutricional, Lima, Peru.
Kathryn M EdwardsVanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
Claudio F LanataInstituto de Investigación Nutricional, Lima, Peru.

Funding

NIH HHS HSN2722001300023I
6 · The paper itself

Abstract

Despite robust antibody responses, immunity induced by acellular pertussis vaccine (DTaP) wanes over time and risk of pertussis seems to be lower in children who receive whole-cell vaccine (DTP) as their first dose. To interrogate the early immunologic response to pertussis vaccine, we enrolled 56 healthy infants who received either DTP or DTaP at 2-, 4-, 6-, and 18-months of age. RNA-sequencing and ribosome profiling of PBMC were performed prior to vaccination (Day 1) and on either Day 2 or Day 8. Pathway enrichment analysis on Days 2 and 8 showed enrichment of TLR-signaling and FcϒR-mediated phagocytosis among DTP recipients. DTP also led to increases in IRAK-4 and IL-1ß. After booster vaccination, a higher frequency of PT-specific B-cells was observed in DTP- vs. DTaP recipients. These data provide insights into the early immunologic responses to pertussis vaccine and may guide next-generation pertussis vaccine development.

Identifiers

PMID40790123
PMCPMC12340008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.